Scarica l'app Stockscreener
29.88
1.52%
-0.46
Dopo l'orario di chiusura:
29.94
0.06
+0.20%
Precedente Chiudi:
$30.34
Aprire:
$29
Volume 24 ore:
1.83M
Relative Volume:
0.44
Capitalizzazione di mercato:
$1.64B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-7.6224
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
+7.52%
1M Prestazione:
-49.32%
6M Prestazione:
+136.21%
1 anno Prestazione:
+342.67%
Intervallo 1D:
$28.79
$30.73
Intervallo di 1 settimana:
$25.24
$31.43
Portata 52W:
$5.50
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
29.88 | 1.89B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
uniQure NV Hits Day High with 15.18% Surge Amid Market Volatility - Markets Mojo
Can uniQure N.V. (UQ1) stock sustain revenue momentumRisk Management & Daily Profit Maximizing Tips - newser.com
uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Yahoo Finance
Volatility clustering patterns for uniQure N.V.Earnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
How institutional buying supports uniQure N.V. stock2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
What catalysts could drive uniQure N.V. stock higherJuly 2025 Institutional & Scalable Portfolio Growth Methods - newser.com
Why uniQure N.V. stock is rated strong buyWeekly Gains Report & Verified Entry Point Detection - Fundação Cultural do Pará
Predicting uniQure N.V. trend using moving averagesMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
UniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsQURE - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
Risk adjusted return profile for uniQure N.V. analyzedRate Cut & Daily Profit Maximizing Trade Tips - newser.com
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
FDA Unveils New Path for Approving Rare Disease Drugs for Just One Person - Bloomberg.com
What data driven models say about uniQure N.V.’s future2025 Momentum Check & Daily Stock Trend Reports - newser.com
Makary, Prasad outline pathway for bespoke gene therapy - statnews.com
Uniqure’s CEO dined with investors. Here’s what he said - statnews.com
Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Yahoo Finance
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Investors to Connect - ACCESS Newswire
uniQure (QURE): Wells Fargo Adjusts Price Target to $60, Maintai - GuruFocus
Can uniQure N.V. stock hit record highs againJuly 2025 Selloffs & Short-Term High Return Ideas - newser.com
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
uniQure NV Hits Day High with 17.93% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - Insider Monkey
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $45 to $60 - 富途牛牛
Liquidity Mapping Around (QURE) Price Events - news.stocktradersdaily.com
uniQURE N.V. Investigation: Investors Encouraged to Contact Kirby McInerney LLP - The AI Journal
uniQure’s Bumpy Ride: Stock Price Prospects - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages uniQure N.V. (QURE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure N.V. (NASDAQ:QURE) Q3 2025 Earnings Call Transcript - Insider Monkey
Chardan Capital Maintains 'Buy' Rating on QURE with $53 Price Ta - GuruFocus
Leerink Partners Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
UniQure: Q3 Earnings Snapshot - ctinsider.com
William Blair reiterates Market Perform rating on uniQure stock amid AMT-130 uncertainty - Investing.com UK
UniQure outlines urgent FDA engagement for AMT-130 as BLA timing turns uncertain - MSN
10 Stocks on a Hot Streak - Insider Monkey
Decoding uniQure NV (QURE): A Strategic SWOT Insight - GuruFocus
uniQure Reports Q3 2025 Results and Clinical Progress - TipRanks
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Uniqure NV earnings missed by $0.47, revenue fell short of estimates - Investing.com South Africa
uniQure N.V. Earnings Call: Pipeline Progress Amid Challenges - TipRanks
QURE: Leerink Partners Lowers Price Target, Maintains Outperform Rating | QURE Stock News - GuruFocus
uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Da - GuruFocus
uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges - Yahoo Finance
uniQure (QURE) Faces Uncertainty in BLA Submission Despite Positive AMT-130 Data - GuruFocus
From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside (NASDAQ:QURE) - Seeking Alpha
uniQure (QURE) Reveals Promising Data Amid Regulatory Challenges - GuruFocus
uniQure (QURE) Q3 2025 Earnings Call Transcript - AOL.com
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Nov 06 '25 |
Sale |
27.26 |
31,434 |
856,881 |
40,145 |
| Kaye Jack | Director |
Nov 04 '25 |
Option Exercise |
9.88 |
38,810 |
383,535 |
38,249 |
| Kaye Jack | Director |
Nov 04 '25 |
Sale |
30.34 |
38,810 |
1,177,517 |
20,439 |
1.43%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):